Hussman Strategic Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.19M | Buy |
147,000
+63,000
| +75% | +$1.37M | 0.73% | 40 |
|
|
2025
Q1 | $2.04M | Sell |
84,000
-21,000
| -20% | -$509K | 0.49% | 80 |
|
|
2024
Q4 | $2.19M | Hold |
105,000
| – | – | 0.65% | 51 |
|
|
2024
Q3 | $2.09M | Hold |
105,000
| – | – | 0.51% | 88 |
|
|
2024
Q2 | $1.63M | Hold |
105,000
| – | – | 0.45% | 99 |
|
|
2024
Q1 | $1.67M | Sell |
105,000
-52,500
| -33% | -$837K | 0.39% | 101 |
|
|
2023
Q4 | $2.65M | Hold |
157,500
| – | – | 0.6% | 59 |
|
|
2023
Q3 | $1.84M | Buy |
157,500
+64,500
| +69% | +$754K | 0.35% | 119 |
|
|
2023
Q2 | $1.25M | Hold |
93,000
| – | – | 0.23% | 188 |
|
|
2023
Q1 | $1.54M | Buy |
93,000
+31,000
| +50% | +$514K | 0.24% | 172 |
|
|
2022
Q4 | $1.15M | Hold |
62,000
| – | – | 0.19% | 187 |
|
|
2022
Q3 | $795K | Sell |
62,000
-68,000
| -52% | -$872K | 0.14% | 229 |
|
|
2022
Q2 | $911K | Buy |
130,000
+62,000
| +91% | +$434K | 0.16% | 210 |
|
|
2022
Q1 | $564K | Hold |
68,000
| – | – | 0.11% | 248 |
|
|
2021
Q4 | $460K | Sell |
68,000
-56,000
| -45% | -$379K | 0.1% | 256 |
|
|
2021
Q3 | $657K | Hold |
124,000
| – | – | 0.14% | 210 |
|
|
2021
Q2 | $713K | Buy |
+124,000
| New | +$713K | 0.15% | 229 |
|